Viking Therapeutics, Inc.: share-based compensation expense
Share-based compensation expense for Viking Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Viking Therapeutics, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 40,818,000 | USD | 2026-02-11 | 10-K · 0001193125-26-046876 |
| 2024-01-01 | 2024-12-31 | 29,712,000 | USD | 2026-02-11 | 10-K · 0001193125-26-046876 |
| 2023-01-01 | 2023-12-31 | 16,750,000 | USD | 2026-02-11 | 10-K · 0001193125-26-046876 |
| 2022-01-01 | 2022-12-31 | 8,673,000 | USD | 2025-02-26 | 10-K · 0000950170-25-027824 |
| 2021-01-01 | 2021-12-31 | 6,100,000 | USD | 2024-02-07 | 10-K · 0000950170-24-012322 |
| 2020-01-01 | 2020-12-31 | 5,818,000 | USD | 2022-02-09 | 10-K · 0001564590-22-004429 |
| 2019-01-01 | 2019-12-31 | 3,743,000 | USD | 2021-02-17 | 10-K · 0001564590-21-006406 |
| 2018-01-01 | 2018-12-31 | 2,608,000 | USD | 2020-02-26 | 10-K · 0001564590-20-006766 |
| 2017-01-01 | 2017-12-31 | 1,451,000 | USD | 2019-03-13 | 10-K · 0001564590-19-007584 |
| 2016-01-01 | 2016-12-31 | 1,794,327 | USD | 2018-03-07 | 10-K · 0001564590-18-004757 |
| 2015-01-01 | 2015-12-31 | 2,601,448 | USD | 2017-03-21 | 10-K · 0001564590-17-004911 |
| 2014-01-01 | 2014-12-31 | 6,258 | USD | 2016-03-08 | 10-K · 0001564590-16-014212 |
Related financial histories
- Viking Therapeutics, Inc.: total assets
- Viking Therapeutics, Inc.: total liabilities
- Viking Therapeutics, Inc.: stockholders equity
- Viking Therapeutics, Inc.: cash and cash equivalents
- Viking Therapeutics, Inc.: net income or loss
- Viking Therapeutics, Inc.: operating cash flow
- Viking Therapeutics, Inc.: revenue
- Viking Therapeutics, Inc.: contract revenue excluding tax
- Viking Therapeutics, Inc.: financing cash flow
- Viking Therapeutics, Inc.: investing cash flow
- Viking Therapeutics, Inc.: retained earnings or deficit
- Viking Therapeutics, Inc.: basic weighted-average shares
- Viking Therapeutics, Inc.: diluted weighted-average shares
- Viking Therapeutics, Inc.: basic earnings per share
- Viking Therapeutics, Inc.: diluted earnings per share
- Viking Therapeutics, Inc.: income tax expense or benefit
- Viking Therapeutics, Inc.: operating income or loss
- Viking Therapeutics, Inc.: current assets
- Viking Therapeutics, Inc.: current liabilities
- Viking Therapeutics, Inc.: current accounts payable
- Viking Therapeutics, Inc.: common-stock repurchase payments
- Viking Therapeutics, Inc.: operating expenses
- Viking Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Viking Therapeutics, Inc. / CIK 0001607678
- Captured
- 2026-09-20T09:26:18.703Z
- SEC response SHA-256
c741f2f24971a4d10aa37b1e293b8d464b95b23c0fecb58db502cd6edd5b0617
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001607678.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))